Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07465653 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07465653 is a Phase 1 study that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT07465653, a Phase 1 study, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
Interventions
- OTHER Placebo
- DRUG HJB647 low dose
- DRUG HJB647 high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-03-18 |
| Est. Completion | 2026-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07465653
The ClinicalTrials.gov registry entry for NCT07465653 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07465653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07465653 about?
NCT07465653 is a clinical study titled "A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
What is the current status of trial NCT07465653?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-03-18. Estimated completion is 2026-09-24.
What interventions are being tested in trial NCT07465653?
The interventions under investigation include: Placebo (OTHER), HJB647 low dose (DRUG), HJB647 high dose (DRUG).
Who is sponsoring clinical trial NCT07465653?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.